Want to see CCM full AI Analyst Report?
CCM Stock Chart & Stats
$4.80
-$0.04(-0.90%)
At close: 4:00 PM EST
$4.80
-$0.04(-0.90%)
Day’s Range― - ―
52-Week Range$3.18 - $6.98
Previous CloseN/A
Volume954.00
Average Volume (3M)25.64K
Market Cap
$22.79M
Enterprise Value$3.34B
Total Cash (Recent Filing)$297.79M
Total Debt (Recent Filing)$3.63B
Price to Earnings (P/E)―
Beta0.64
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,815,458
10 Day Avg. Volume72,657
30 Day Avg. Volume25,639
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)>-0.01
Price to Sales (P/S)0.00853
P/FCF Ratio-0.01
Enterprise Value/Market Cap146.64
Enterprise Value/Revenue5.71
Enterprise Value/Gross Profit82.91
Enterprise Value/Ebitda-27.58
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
2025 Revenue ReboundThe strong 2025 revenue rebound indicates renewed demand for oncology services after the prior-year decline. If sustained, higher patient volumes and equipment utilization could improve operating leverage, though profitability still needs to follow.
Improving Losses And Cash BurnThe reduction in net losses and materially better free cash flow show progress from the 2024 trough. Continued improvement could reduce financing dependence over time, although cash generation remains negative and the business is not yet self-funding.
Management ContinuityThe interim CFO appointment provides an established internal leadership resource during a finance transition. His long tenure across the group may help preserve operational knowledge and execution continuity in the oncology-focused healthcare business.
Bears Say
Persistent UnprofitabilityRecurring operating and net losses indicate that revenue recovery has not yet produced a sustainable earnings model. Volatile or negative gross profit also suggests cost pressure and limited pricing power, weakening the durability of future profitability.
Ongoing Cash BurnNegative operating and free cash flow mean core operations continue to consume cash rather than fund investment and obligations. Persistent cash burn can force reliance on refinancing, asset sales, or new capital, especially while leverage remains elevated.
Highly Leveraged Balance SheetSubstantial debt combined with negative equity materially limits financial flexibility and increases financing risk. Even after debt declined from 2024, the weakened capital structure leaves less capacity to absorb operating setbacks or fund oncology expansion.
Concord Medical Services News
CCM FAQ
What was Concord Medical Services’s price range in the past 12 months?
Concord Medical Services lowest stock price was $3.18 and its highest was $6.98 in the past 12 months.
What is Concord Medical Services’s market cap?
Concord Medical Services’s market cap is $22.79M.
When is Concord Medical Services’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Concord Medical Services’s earnings last quarter?
Currently, no data Available
Is Concord Medical Services overvalued?
According to Wall Street analysts Concord Medical Services’s price is currently Overvalued.
Does Concord Medical Services pay dividends?
Concord Medical Services pays a Notavailable dividend of $0.99 which represents an annual dividend yield of N/A. See more information on Concord Medical Services dividends here
What is Concord Medical Services’s EPS estimate?
Concord Medical Services’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Concord Medical Services have?
Concord Medical Services has 2,815,458 shares outstanding.
What happened to Concord Medical Services’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Concord Medical Services?
Currently, no hedge funds are holding shares in CCM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Concord Medical Services
Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People’s Republic of China. It operates in two segments, Network and Hospital. The company’s services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, China.
Technical Analysis
American Shared Hospital Services
―
Joint
―
Cryo-Cell International
―
DocGo
―
P3 Health Partners
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.49% Other Institutional Investors
99.51% Public Companies and
Individual Investors